Company Filing History:
Years Active: 1996
Title: The Innovations of Tiit Land in Pharmaceutical Development
Introduction
Tiit Land, a notable inventor based in Stockholm, Sweden, holds a pivotal patent in the realm of pharmacology. His innovation focuses on a galanin antagonist, contributing significant advancements to the treatment of various disorders linked to the physiological functions of galanin.
Latest Patents
Tiit Land is credited with a unique patent that describes a galanin receptor ligand. This patent introduces several new peptides, including Galanin (1-12)-Pro-Substance P(5-11), Galanin (1-12)-Pro-Bradykinin(2-9), Galanin (1-12)-Pro-Pro-Pro-(Leu.sup.5 -Enkephalin (5-1), and Galanin (1-12)-Pro-Lys(.epsilon.-NH-)Pro-(Leu5-Enkephalin (5-1). These compounds and their functional analogues and derivatives demonstrate the potential for pharmaceutical applications to effectively treat disorders dependent on galanin's function at its receptor.
Career Highlights
Tiit Land has made significant strides in his career as a researcher and inventor. With a sole patent to his name, he has positively impacted the pharmaceutical industry. His work at Aktiebolaget Astra highlights his commitment to advancing medical science and improving therapeutic options.
Collaborations
Throughout his career, Tiit Land has worked alongside esteemed colleagues, including Tamas Bartfai and Tomas Hökfelt. These collaborations have contributed to a rich exchange of ideas and innovations in the field of pharmaceutical research, bolstering the development of groundbreaking therapies.
Conclusion
Tiit Land's innovative contributions highlighted by his galanin antagonist patent make him a key figure in the pharmaceutical landscape. His ongoing work and collaborations emphasize the importance of research and invention in addressing medical challenges. With a focus on improving health outcomes, Tiit Land continues to be a notable inventor whose contributions will shape the future of therapeutic developments.